Di Bello Elisabetta, Zwergel Clemens, Mai Antonello, Valente Sergio
Department of Drug Chemistry and Technologies, Sapienza University of Rome, Rome, Italy.
Department of Precision Medicine, Luigi Vanvitelli, University of Campania, Naples, Italy.
Front Chem. 2020 Jun 18;8:516. doi: 10.3389/fchem.2020.00516. eCollection 2020.
Numerous and different types of cancers possess the dysregulation of the mevalonate pathway as a common feature. Statins, traditionally applied in cardiovascular diseases to reduce lipid levels, subsequently have been discovered to exhibit anti-cancer activities also. Indeed, statins influence proliferation, migration, and survival of cancer cells by regulating crucial signaling proteins, such as Rho, Ras, and Rac. Recently, several studies have demonstrated that simvastatin, fluvastatin, and lovastatin are implicated in different pathways that enhance the survival time of patients with cancer under treatment in combination with antineoplastic agents. In this minireview, we present an overview of the most important studies conducted regarding the use of statins in cancer therapy up to date.
许多不同类型的癌症都具有甲羟戊酸途径失调这一共同特征。他汀类药物传统上用于治疗心血管疾病以降低血脂水平,随后人们发现它们也具有抗癌活性。事实上,他汀类药物通过调节关键信号蛋白,如Rho、Ras和Rac,来影响癌细胞的增殖、迁移和存活。最近,多项研究表明,辛伐他汀、氟伐他汀和洛伐他汀参与了不同的途径,这些途径可延长癌症患者在与抗肿瘤药物联合治疗时的生存时间。在这篇小型综述中,我们概述了迄今为止有关他汀类药物在癌症治疗中的应用的最重要研究。